Journal of vascular and interventional radiology : JVIR
-
J Vasc Interv Radiol · Nov 2012
Randomized Controlled Trial Multicenter Study Comparative StudyDoes age of fracture affect the outcome of vertebroplasty? Results from data from a prospective multicenter FDA IDE study.
To evaluate whether the age of a fracture is a variable that can identify patients for whom vertebroplasty would be most beneficial. ⋯ Results of the study showed that the age of a fracture does not independently affect the outcomes of vertebroplasty.
-
J Vasc Interv Radiol · Nov 2012
Comparative StudyPercutaneous vertebroplasty and kyphoplasty for pathologic vertebral fractures in the Medicare population: safer and less expensive than open surgery.
To compare cost and outcomes of surgical and percutaneous treatments of pathologic vertebral fractures. ⋯ In a Medicare population with bony malignancy and vertebral fractures, percutaneous therapy predicted significantly reduced cost and length of stay versus surgery. Patients who underwent percutaneous therapy were significantly less likely to die, be transferred, or be discharged to rehabilitation facilities, and were more likely to be discharged to home or hospice.
-
J Vasc Interv Radiol · Nov 2012
Letter Case ReportsSpinal cord needle tract following epidural steroid injection.
-
J Vasc Interv Radiol · Oct 2012
Multicenter StudyPhase I/II multicenter study of transarterial chemoembolization with a cisplatin fine powder and porous gelatin particles for unresectable hepatocellular carcinoma: Japan Interventional Radiology in Oncology Study Group Study 0401.
A multicenter phase I/II study of transarterial chemoembolization with a fine cisplatin powder and gelatin particles (GPs) for multifocal hepatocellular carcinoma (HCC) was conducted. Primary endpoints were dose-limiting toxicity (DLT) and recommended dose (RD). Secondary endpoints were the incidence and severity of adverse events and tumor response. ⋯ Nonselective transarterial chemoembolization with fine cisplatin powder and GPs was well tolerated and effective in patients with multifocal HCC at the RD of 65 mg/m(2).
-
J Vasc Interv Radiol · Oct 2012
Comparative StudySafety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
The aim of this study was to investigate the safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma (HCC) after doxorubicin drug-eluting bead (DEB) transarterial chemoembolization and to elucidate the factors predisposing to overnight admission. ⋯ Same-day discharge after superselective DEB transarterial chemoembolization for unresectable HCC is safe and feasible. BCLC C or D stage of disease, a higher Charlson comorbidity score, and groin or closure device complications are correlated with a greater likelihood for overnight admission.